Takeda Pharmaceutical (BOVESPA:TAKP34) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

TAKP34 Overzicht aandelen

Takeda Pharmaceutical Company Limited houdt zich bezig met onderzoek, ontwikkeling, productie, marketing en het in licentie geven van farmaceutische producten in Japan en daarbuiten.

Over het bedrijf

TAKP34 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	3/6
Prestaties in het verleden	1/6
Financiële gezondheid	3/6
Dividenden	4/6

Beloningen

Verhandeld tegen 42.1% onder onze schatting van de reële waarde

De winst zal naar verwachting met 22.4% per jaar groeien

Risicoanalyse

De schulden worden niet goed gedekt door de operationele kasstroom

Winstmarges (3.4%) zijn lager dan vorig jaar (7.3%)

Grote eenmalige posten die de financiële resultaten beïnvloeden

Dividend van 4.73% wordt niet goed gedekt door de winst

Takeda Pharmaceutical Company Limited Concurrenten

Hypera

BOVESPA:HYPE3

R$16.8b

Ouro Fino Saúde Animal Participações

BOVESPA:OFSA3

R$1.1b

Sun Pharmaceutical Industries

NSEI:SUNPHARMA

₹4.6t

Jiangsu Hengrui Medicine

SHSE:600276

CN¥332.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Takeda Pharmaceutical
Historische aandelenkoersen
Huidige aandelenkoers	JP¥80.88
52 Week Hoogtepunt	JP¥84.50
52 Week Laag	JP¥66.46
Bèta	0.50
11 maand verandering	-4.28%
3 maanden verandering	11.05%
1 Jaar Verandering	7.78%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	15.54%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	TAKP34	BR Pharmaceuticals	BR Markt
7D	0%	3.0%	0.5%
1Y	7.8%	-10.9%	10.5%

Rendement versus industrie: TAKP34 overtrof de BR Pharmaceuticals industrie, die het afgelopen jaar een rendement -10.9 % opleverde.

Rendement versus markt: TAKP34 presteerde slechter dan BR Market, dat het afgelopen jaar een rendement van 10.5 % opleverde.

Prijsvolatiliteit

Is TAKP34's price volatile compared to industry and market?
TAKP34 volatility
TAKP34 Average Weekly Movement	4.4%
Pharmaceuticals Industry Average Movement	6.3%
Market Average Movement	4.5%
10% most volatile stocks in BR Market	9.2%
10% least volatile stocks in BR Market	2.2%

Stabiele aandelenkoers: TAKP34 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van TAKP34 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1781	49,281	Christophe Weber	www.takeda.com

Takeda Pharmaceutical Company Limited houdt zich bezig met onderzoek, ontwikkeling, productie, marketing en het in licentie geven van farmaceutische producten in Japan en daarbuiten. Het biedt farmaceutische producten op het gebied van gastro-enterologie, zeldzame ziekten, van plasma afgeleide therapieën, immunologie, oncologie en neurowetenschap. Het bedrijf levert zijn producten onder de merknamen Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, en Alunbrig merken.

Takeda Pharmaceutical Company Limited Samenvatting

Hoe verhouden de winst en inkomsten van Takeda Pharmaceutical zich tot de beurswaarde?
TAKP34 fundamentele statistieken
Marktkapitalisatie	R$244.30b
Inkomsten(TTM)	R$5.57b
Inkomsten(TTM)	R$164.08b

43.8x

Koers/Winstverhouding

1.5x

P/S-verhouding

Is TAKP34 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TAKP34 resultatenrekening (TTM)
Inkomsten	JP¥4.41t
Kosten van inkomsten	JP¥1.50t
Brutowinst	JP¥2.92t
Overige uitgaven	JP¥2.77t
Inkomsten	JP¥149.92b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Oct 31, 2024

Winst per aandeel (EPS)	94.60
Brutomarge	66.07%
Nettowinstmarge	3.40%
Schuld/Eigen Vermogen Verhouding	70.3%

Hoe presteerde TAKP34 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

4.7%

Huidig dividendrendement

197%

Uitbetalingsratio

TAKP34 Overzicht aandelen

Beloningen

Risicoanalyse

Takeda Pharmaceutical Company Limited Concurrenten

BOVESPA:HYPE3

R$16.8b

BOVESPA:OFSA3

R$1.1b

NSEI:SUNPHARMA

₹4.6t

SHSE:600276

CN¥332.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Recent updates

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Takeda Pharmaceutical Company Limited Proposes Dividend

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Announces S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year 2023

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda Pharmaceutical Company Limited Announces FDA Approves the Supplemental Biologics License Application for the Expanded Use of TAKHZYRO

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Takeda Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on May 11, 2023

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Takeda Pharmaceutical Company Limited Samenvatting